Harmony Biosciences is executing a powerful commercial inflection, with Q2 2026 revenue surging 30.3% year-over-year to $261.3M and operating margin expanding to 34.2%, the highest in ten quarters, while EPS grew 88.2% to $1.28. The asset-light model generates...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $1.28+33.9% vs $0.96 | $261M+4.2% vs $251M |
Q2 2026 May 7, 2026 | $0.55-27.6% vs $0.76 | $215M-2.5% vs $221M |
Q1 2026 Feb 24, 2026 | $0.38-54.8% vs $0.84 | $244M+1.4% vs $240M |
Q4 2025 Nov 4, 2025 | $0.87-5.4% vs $0.92 | $239M-0.2% vs $240M |
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 800 shares of the firm's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $43.00, for a total transaction of $34,400.00. Following the completion of the transaction, the insider directly owned 13,115 shares in
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 1,800 shares of the business's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $43.01, for a total transaction of $77,418.00. Following the completion of the transaction, the insider directly owned 13,115 shares in
Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Institutional and Insider Ownership 86.2% of Harmony Biosciences
Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?
Benchmark HRMY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Harmony Biosciences Holdings, Inc. (HRMY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $41.53 | $2.4B | 15.32 | 21.51% | 18.27% | 20.75% | — | |
| $240.57 | $15.11B | -41.19 | 4.88% | 20.45% | 21.37% | — | |
| $13.10 | $2.78B | 87.33 | 26.93% | 15.33% | 15.7% | — | |
| $203.10 | $10.45B | -55.19 | 65.55% | -24.68% | -255.6% | — | |
| $20.98 | $1.55B | 6.36 | 18.52% | 80.56% | 30.03% | — | |
| $43.75 | $2.54B | -64.34 | 8.63% | -13.23% | -10.42% | — |
Harmony Biosciences Holdings, Inc. (HRMY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Harmony Biosciences Holdings, Inc. (HRMY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jul 16, 2026·SEC
May 14, 2026·SEC
Get notified when HRMY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Harmony Biosciences Holdings, Inc. (HRMY) stock FAQ — growth, dividends, profitability & financials explained
Harmony Biosciences Holdings, Inc. (HRMY) reported $959.9M in revenue for fiscal year 2025.
Harmony Biosciences Holdings, Inc. (HRMY) grew revenue by 21.5% over the past year. This is strong growth.
Yes, Harmony Biosciences Holdings, Inc. (HRMY) is profitable, generating $181.3M in net income for fiscal year 2025 (18.3% net margin).
Harmony Biosciences Holdings, Inc. (HRMY) has a return on equity (ROE) of 20.8%. This is excellent, indicating efficient use of shareholder capital.
Harmony Biosciences Holdings, Inc. (HRMY) generated $354.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
